期刊文献+

α-硫辛酸联合甲钴胺口服治疗糖尿病周围神经病变 被引量:10

Oral α-lipoic acid combined with methylcobalamin in treatment of diabetic peripheral neuropathy
原文传递
导出
摘要 目的探讨α-硫辛酸联合甲钴胺治疗糖尿病周围神经病变(DPN)的临床疗效及安全性。方法选择DPN患者64例,采取分层随机、开放、对照的研究方法将患者分为试验组32例、对照组32例。患者常规给予饮食控制、胰岛素或口服降糖药将血糖控制在良好范围,维持原降压、调脂等综合治疗,对照组同时给予甲钴胺0.5mg、每日3次口服,试验组同时给予α-硫辛酸600mg、每日1次联合甲钴胺0.5mg、每日3次口服,疗程均为12周。分别在治疗前后记录两组患者的总症状评分(TSS)和神经传导速度(NCV),并观察有无药物不良反应。结果治疗后两组患者TSS评分和NCV均较治疗前有改善(P<0.05)。治疗后试验组的TSS评分低于对照组(P<0.05),治疗后试验组的正中神经运动传导速度、腓总神经运动和感觉传导速度与对照组比较差异有统计学意义(P<0.05)。治疗过程中两组均未见明显的药物不良反应。结论α-硫辛酸联合甲钴胺口服治疗DPN疗效优于单用甲钴胺,而且安全简便,依从性好,值得推广。 Objective To observe the clinical efficacy and safety of oral a-lipoic acid combined with methylcobalamin in treatment of diabetic peripheral neuropathy (DPN). Methods Sixty-four DPN patients were selected and randomly divided into experimental group (n= 32) and control group (n= 32). All the patients were given diet control, insulin or oral hypoglycaemic agent and the blood glucose was satisfactorily controlled; the original antihypertensive and antilipemic therapies were maintained. Meanwhile, patients in the control group were also given oral methylcobalamin (three times per day and each for 0.5 mg), and those in the experimental group were given oral a-lipoic acid (once a day and each for 600 mg) and oral methylcobalamin (three times per day and each for 0. 5 mg) . The total symptom scores (TSS) and the nerve conduction velocity (NCV) were evaluated in the two groups before and 12 weeks after treatment; and the adverse drug reactions were also observed. Results The TSS and NCV were significantly improved in both groups after treatment compared with before treatment (P〈0. 05). After treatment, TSS was significantly lower in the experimental group than in the control group (P〈0.05), and there were significant differences in the transmission velocities of the median motor nerve, nervus peroneus communis motor nerve and its sensory nerve between two groups (P〈0.05). No serious side effects were found in the two groups during the treatment. Conclusion Oral a-lipoic acid combined with methylcobalamin on DPN is superior to methylcobalamin used alone for treatment of DPN, and the combined treatment is simple and has better patient compliance, making it worth popularizing.
出处 《第二军医大学学报》 CAS CSCD 北大核心 2013年第3期306-309,共4页 Academic Journal of Second Military Medical University
基金 上海市自然科学基金(10ZR1439400)~~
关键词 Α-硫辛酸 甲钴胺 口服投药 糖尿病神经病变 a-lipoic acid methylcobalamin oral administrations diabetic neuropathies
  • 相关文献

参考文献11

  • 1张孝丽,郭晖.α硫辛酸治疗糖尿病周围神经病变的研究进展[J].医学综述,2011,17(2):281-283. 被引量:54
  • 2Han T, Bai J, Liu W, Hu Y. A systematic review and meta-analysis of a-lipoic acid in the treatment of diabetic peripheral neuropathy[J]. Eur J Endocrinol, 2012,167 : 465-471.
  • 3Ziegler D, Ametov A, Barinov A, Dyck P J, Gurieva I, Low P A, et al. Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy., the SYDNEY 2 trial [J]. Diabetes Care, 2006, 29: 2365- 2370.
  • 4Young M J,Boulton A J,MacLeod A F,Williams D R, Sonksen P H. A multicentre study of the prevelence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population [J]. Diabetologia, 1993, 36: 150-154.
  • 5Ametov A S, Barinov A, Dyck P J, Hermann R, Kozlova N, Litchy W J,et al. The sensory symptoms of diabetic polyneuropathy are improved with alpha-lipoic acid: the SYDNEY trial[J]. Diabetes Care,2003,26:770-776.
  • 6Callaghan B C, Cheng H T, Stables C L, Smith A L, Feldman E L. Diabetic neuropathy: clinical manifesta- tions and current treatments[J]. Lancet Neurol, 2012, 11 :521-534.
  • 7Chiu C K,Low T H,Tey Y S,Singh V A,Shong H K. The efficacy and safety of intramuscular injections of methylcobalamin in patients with chronic nonspecific low back pain: a randomised controlled trail[J]. Singa- pore Med J,2011,52:868-872.
  • 8Sun Y,Lai M S,Lu C J. Effectiveness of vitamin B12 on diabetic neuropathy: systematic review of clinical con- trolled trials[J]. Acta Neurol Taiwan, 2005,14: 48-54.
  • 9Brownlee M. Biochemistry and molecular cell biology of diabetic complications[J]. Nature, 2001,414 : 813-820.
  • 10Shay K P,Moreau R F,Smith E J,Smith A R,Hagen T M. Alpha-lipoic acid as a dietary supplement : molecular mechanisms and therapeutic potential[J]. Biochim Bio- phys Acta, 2009,1790 : 1149-1160.

二级参考文献20

  • 1张德刚,赵瑛,夏培金,黄霄群,刘志民.褪黑素对糖尿病周围神经病变大鼠氧化应激的作用[J].标记免疫分析与临床,2006,13(4):221-224. 被引量:8
  • 2Cremer DR, Rabeler R, Roberts A,et al.Long-term safety of alipoic acid (ALA) consumption : a 2-year study [ J ]. Regul Toxicol Pharmacol,2006,46 ( 3 ) : 193-201.
  • 3Brownlee M. Biochemistry and molecular cell biology of diabetic complications[ J]. Nature ,2001,414(6865 ) :813-820.
  • 4Du XL, Edelstein D, Dimmeler S, et al. Hyperglycemia inhibits endotheial nitric oxide synthase activity by posttranslational modifica- tion at theAkt site [ J ]. J Clin Invest,2001,108 ( 9 ) : 1341-1348.
  • 5Du X, Matsumura T, Edelstein D, et al. Inhibition of GAPDH activity bypoly(ADP-ribose) polymerase activates three major pathways of hyperglycemic damage in endothelial ceils [ J ]. J Clin Invest,2003,112 ( 7 ) : 1049-1057.
  • 6van Dam PS. Oxidative stress and diabetic neuropathy:pathophysiological mechanisms and treatment perspectives [ J ]. Diabetes Metab Res Rev,2002,18 (3) : 176-184.
  • 7Moikawa T, Yasuno R, Wada H. Domammalian cells synthesize lipoic acid? Identification of a mouse cDNA encoding a lipoic acid synthase located in mitochondria [ J]. FEBS Lett,2001,498 ( 1 ) : 16-21.
  • 8Packer L, Kraemcr K, Rimbach G. Molecular aspects of lipoic acid in the prevention of diabetes complications [ J ]. Nutrition,2001,17 (10) :888-895.
  • 9Baydas G, Donder E, Kiliboz M, et al. Neuroprotectlon by alpha- lipoic acid in streptozotocin-indueed diabetes [ J ]. Biochemistry (Mosc) ,2004,69 (9) : 1001-1005.
  • 10Jain SK, Lim G. Lipoic acid decreases lipid peroxidation and protein glycesylation and increases ( Na^++ K^+) -and Ca^2+ -ATPase activitiesin high glucosetreated human erythrocytes[ J]. Free Radic Biol Med ,2000 ,29 ( 11 ) : 1122-1128.

共引文献53

同被引文献106

  • 1方向明,王玉容,叶文春,高莉,刘小英,杨白林,漆晓玲,谯艳.鼠神经生长因子联合甲钴胺治疗糖尿病周围神经病变的疗效观察[J].四川医学,2012,33(11):1968-1970. 被引量:9
  • 2邵泽平,乔瑞花,刘溪.α-硫辛酸联合弥可保治疗糖尿病周围神经病变的临床观察[J].中国医学工程,2011,19(2):100-101. 被引量:5
  • 3李坤.注射用鼠神经生长因子治疗缺血性视神经病变的疗效观察[J].中国生化药物杂志,2014,34(6):130-132. 被引量:24
  • 4王杨,刘畅.依帕司他治疗糖尿病周围神经病变的疗效及机制[J].中国老年学杂志,2015,35(1):93-95. 被引量:77
  • 5迟佳敏.实用糖尿病学[M].第3版.北京:人民卫生出版社,2009.193-194.
  • 6Martin C L, Waberski B H, Pop-Busui R, et al. Vibration perception threshold as a measure of distal symmetrical peripheral neuropathy in type 1 diabetes: results from the DCCT/EDIC study [J]. Diabetes Care, 2010, 33(12):2635-2641.
  • 7林华容,李壮丰,陆静明.鼠神经生长因子治疗糖尿病周围神经病变的临床电生理和安全性观察[A]//中华医学会、中华医学会糖尿病分会.中华医学会糖尿病学分会第十六次全国学术会议论文集[C]中华医学会、中华医学会糖尿病分会,2012:105-106.
  • 8程伟进,胡红玲,丁咯地尔与甲钴胺联合治疗糖尿病周围神经病的临床观察[A]//浙江省医学会神经病学分会2009年浙江省神经病学学术年会论文汇编[C].浙江省医学会神经病学分会,2009:120-121.
  • 9Palacka P,Kucharska J,Murin J,et aI.Complementary therapy in diabetic patients with chronic comptications,a pilot study[J].Bratial Lek Listy, 2010,111(4):205-211.
  • 10Tesfaye S, Bouhon A J M, Dyck P J, et al. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments[J]. Diabetes Care, 2010, 33 ( 10 ) : 2285-2293.

引证文献10

二级引证文献147

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部